Women with a history of gestational diabetes mellitus (GDM) are at higher risk of developing type 2 diabetes (T2DM); however, little is known about the association between other common pregnancy complications (eg, preterm birth, macrosomia) and T2DM risk. We examined the associations between first-pregnancy preterm, postterm birth, low birth weight, and macrosomia with subsequent risk of T2DM.
We conducted a prospective cohort study of Nurses’ Health Study II (NHSII) participants; 51,728 women in the study had a single live birth and complete pregnancy history. NHSII confirmed incident diabetes mellitus through supplemental questionnaires. Participants were followed from year of first birth until 2005. We defined gestational age as very preterm (20 to ≤32 weeks), moderate preterm (33 to ≤37 weeks), term (38 to ≤42 weeks), and postterm (≥43 weeks). We defined low birth weight as an infant born at term weighing less than 5.5 pounds, and we defined macrosomia as an infant born at term weighing 10 pounds or more. We used Cox proportional hazards models, adjusting for potential confounders.
Women with a very preterm birth (2%) had an increased T2DM risk (adjusted hazard ratio, 1.34; 95% confidence interval [CI], 1.05–1.71). This increased risk emerged in the decade following pregnancy. Macrosomia (1.5%) was associated with a 1.61 increased T2DM risk, after adjusting for risk factors, including GDM (95% CI, 1.24–2.08). This association was apparent within the first 5 years after pregnancy. Moderate preterm and term low birth weight did not significantly increase the risk of T2DM over the 35-year follow-up time.
Women who experienced a very preterm birth or had an infant that weighed 10 pounds or more may benefit from lifestyle intervention to reduce T2DM risk. If replicated, these findings could lead to a reduced risk of T2DM through improved primary care for women experiencing a preterm birth or an infant of nonnormal birth weight.
A growing body of research suggests that pregnancy and the period surrounding it may provide unique information about a woman’s future risk of chronic disease (
Despite the well-established association between GDM and future risk of T2DM (
The objective of our study was to examine the association between gestational age, birth weight, and T2DM in mothers. We evaluated these associations in a large cohort study, adjusting for potential confounders, including maternal and paternal history of diabetes, pre-pregnancy body mass index (BMI), and smoking during pregnancy. We also adjusted for lifestyle and reproductive factors as well as pregnancy complications known to be predictors of T2DM. Finally, we explored the time trends in risk over the decades following birth of a preterm infant or an infant of nonnormal birth weight to suggest potential windows for prevention and glucose tolerance screening after complicated pregnancies.
Study participants were from the Nurses’ Health Study II (NHSII) population, a cohort study of 116,678 female nurses who were aged 25 to 42 years at the start of the study in 1989. NHSII follows participants biennially by questionnaire to obtain both health-related behavior information and data on the occurrence of diseases, including diabetes. The follow-up rate has been approximately 90% for each biennial questionnaire. For purposes of this study, we followed women from their first pregnancy (the earliest pregnancy in our study population occurred in 1964) through 2005, the last reported follow-up for incident diabetes.
Our study population is based on a subset of the NHSII population who had detailed data on pregnancy history and T2DM. More specifically, in 2001, NHSII sent a supplemental questionnaire to study participants who were deemed good responders — those women who typically responded to the first or second mailing of the biennial questionnaires. This supplemental questionnaire included detailed data on history of pregnancies that lasted at least 12 weeks; 68,376 women (75% of those mailed the supplemental questionnaire and 58% of the original study population) returned the questionnaire (
Characteristics of the study population, 2001 Nurses’ Health Study II supplemental questionnaire.
Study participants indicated the length of each of their 5 most recent pregnancies lasting at least 12 weeks in the following categories: 12 to less than 20 weeks, 20 to less than 24 weeks, 24 to less than 28 weeks, 28 to less than 32 weeks, 32 to less than 37 weeks, 37 to 42 weeks, and 43 or more weeks. Pregnancies were categorized as very preterm (20 to ≤32 weeks), moderate preterm (33to ≤37 weeks), term (37 to ≤42 weeks, referent) and postterm (≥43 weeks).
Participants were asked the birth weight for each of their 5 most recent pregnancies (<5 lbs, 5–5.4 lbs, 5.5–6.9 lbs, 7.0–8.4 lbs, 8.5–9.9 lbs, ≥10 lbs). Low birth weight was defined as less than 5.5 pounds at term and macrosomia as 10 pounds or more at term.
In the NHSII 1989 baseline questionnaire and subsequent biennial questionnaires study participants indicated whether they had ever been diagnosed with GDM by a physician. A validation of GDM showed high validity of self-report of this condition compared with medical records (
Study participants responded to “Have you ever had toxemia/pre-eclampsia (raised blood pressure and proteinuria) with any pregnancy?” on the NHSII baseline questionnaire and biennially. A recent validation of pre-eclampsia compared with medical record review showed self-reported preeclampsia is a moderately good indicator of hypertensive disorders of pregnancy (HDOP) (positive predictive value, 73%) (
NHSII study participants received a supplemental questionnaire if they reported having been diagnosed with diabetes mellitus on the biennial questionnaires between 1991 and 2005. These supplemental questionnaires collected information to distinguish between type 1 and type 2 diabetes mellitus on the basis of diabetes diagnosis and treatment. The validation of this method of case confirmation has been reported previously (
On the 1989 baseline questionnaire, study participants reported their current weight and height and their weight at age 18 (
Participants reported their race/ethnicity at baseline. Subsequent biennial questionnaires queried family history of diabetes mellitus, as well as a personal medical history (eg, hypertension, cancer, gestational diabetes, pre-eclampsia, toxemia). In addition, the 2001 supplemental questionnaire asked about smoking status during pregnancy (eg, ever, never). Participants were also asked at baseline to report their menstrual regularity at age 18 to 22 years, which was categorized as regular, irregular, or no menstrual periods.
We used Cox proportional hazards models to examine the association between preterm and postterm birth, as well as low birth weight and macrosomia with T2DM risk, modeling gestational age and birth weight separately. Very preterm birth, moderate preterm birth, and postterm birth were evaluated as indicator variables, with the reference group of term. For the association between birth weight and T2DM, we did not have enough information on birth weights under 5.5 pounds to create small-for-gestational-age categories among preterm births. Therefore, we restricted our analysis to women who had a term birth (n = 42,502). Models were constructed among all term births by using indicator variables for low birth weight, macrosomia, and normal birth weight (reference group).
Women were followed from their first birth through 2005 or up to 35 years after their first pregnancy; we were able to follow more than 95% of the cohort for up to 34 years after their first birth. First, we evaluated the association between gestational age, infant birth weight, and T2DM risk in first pregnancies for the entire 35-year follow-up period. Second, we explored time since first birth in 5-year intervals up to 35 years after the first pregnancy to determine at what time points the differences between gestational age or birth-weight groups were significant. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. We adjusted for potential confounders, those factors that preceded pregnancy complications of interest and were associated with diabetes mellitus. Finally, we used the Breslow estimator to calculate the age-adjusted risk differences from the Cox proportional hazards models. All analyses were conducted using SAS statistical software (version 9.3; SAS Institute, Inc, Cary, North Carolina).
In our study population of NHSII participants, births occurred between 1964 and 2001, with 95% occurring before 1993. We examined pregnancy complications and risk factors for all births and for term births in the study population (
| Characteristic | All Births | Term Births | ||||||
|---|---|---|---|---|---|---|---|---|
| Total Births | Very Preterm | Moderate Preterm | Term | Postterm | Low Birth Weight | Normal Birth Weight | Macro- somia | |
| Total no. (%) | 51,728 (100) | 1,088 (2.1) | 3,460 (6.7) | 42,502 (82.2) | 4,678 (9.0) | 554 (1.3) | 41,294 (97.2) | 654 (1.5) |
| Age at first birth, mean (SD) | 27.1 (4.7) | 27.3 (5.4) | 27.7 (4.8) | 27.1 (4.7) | 26.6 (4.5) | 26.9 (5.0) | 27.1 (4.6) | 27.6 (4.5) |
| Age at 1989 baseline, mean (SD) | 34.6 (4.7) | 35.4 (4.5) | 34.1 (4.7) | 34.5 (4.7) | 35.4 (4.5) | 35.8 (4.6) | 34.5 (4.7) | 34.0 (4.7) |
| BMI at 1st pregnancy, mean (SD) | 22.1 (3.1) | 22.3 (3.6) | 22.2 (3.2) | 22.1 (3.1) | 22.3 (3.3) | 21.9 (2.9) | 22.0 (3.0) | 23.8 (4.4) |
| BMI in 1989, mean (SD) | 23.8 (4.6) | 24.2 (4.9) | 23.5 (4.5) | 23.7 (4.5) | 24.7 (5.3) | 23.7 (4.6) | 23.7 (4.5) | 25.7 (5.6) |
| White, n (%) | 48,292 (93.4) | 999 (91.8) | 3,171 (91.7) | 39,705 (93.4) | 4,417 (94.4) | 505 (91.2) | 38,577 (93.4) | 623 (95.3) |
| Family history of diabetes | 15,457 (29.9) | 367 (33.7) | 1,127 (32.6) | 12,512 (29.4) | 1,451 (31.0) | 175 (31.6) | 12,125 (29.4) | 212 (32.4) |
| GDM status, n (%) | 2,882 (5.6) | 86 (7.9) | 245 (7.1) | 2,280 (5.4) | 271 (5.8) | 27 (4.9) | 2,164 (5.2) | 89 (13.6) |
| HDOP status, n (%) | 7,653 (14.8) | 219 (20.1) | 841 (24.3) | 5,824 (13.7) | 769 (16.4) | 135 (24.4) | 5,560 (13.5) | 129 (19.7) |
| Smoking during pregnancy, n (%) | 7,104 (13.7) | 178 (16.4) | 452 (13.1) | 5,727 (13.5) | 747 (16.0) | 132 (23.8) | 5,534 (13.4) | 61 (9.3) |
| Irregular or no menstrual periods at age 18–22, n (%) | 11,941 (23.1) | 305 (28.0) | 790 (22.8) | 9,550 (22.5) | 1,296 (27.7) | 120 (21.7) | 9,297 (22.5) | 133 (20.3) |
Abbreviations: SD, standard deviation; BMI, body mass index; GDM, gestational diabetes mellitus; HDOP, history of hypertensive disorders of pregnancy.
Participant’s mother or father diagnosed with diabetes.
In age-adjusted analysis, we observed a graded association of very and moderate preterm birth with risk of T2DM, as well as elevated risks among women delivering their first child postterm (
| Birth | N (%) | Age-Adjusted Hazard Ratio (95% Confidence Interval) | Adjusted Hazard Ratio (95% Confidence Interval) |
|---|---|---|---|
| Very preterm | 1,088 (2.1) | 1.65 (1.30–2.11) | 1.34 (1.05–1.71) |
| Moderate preterm | 3,460 (6.7) | 1.34 (1.13–1.58) | 1.12 (0.95–1.32) |
| Term | 42,502 (82.2) | Reference | Reference |
| Postterm | 4,678 (9.0) | 1.29 (1.13–1.48) | 1.15 (1.00–1.32) |
Adjusted for age in 1989.
Adjusted for maternal age at first birth, age in 1989, race/ethnicity, pre-pregnancy body mass index, family history of diabetes, menstrual irregularity, smoking during pregnancy, history of gestational diabetes mellitus, history of hypertensive disorders of pregnancy.
We explored the association between gestational age and T2DM in 5-year intervals following first pregnancy (
Association between gestational age and incidence of type 2 diabetes by 5-year intervals following first pregnancy adjusted for age at first birth, age at baseline Nurses’ Health Study II, race/ethnicity, pre-pregnancy body mass index, family history of diabetes, menstrual irregularity, smoking during pregnancy, gestational diabetes, and hypertensive disorders of pregnancy. Abbreviations: CI, confidence interval; NA, not applicable.
Total Number of Diabetes Cases in 5-Year Intervals Adjusted Hazard Ratio (95% Confidence Interval) 5 years, n = 52 Very preterm, n = 2 0.93 (0.22–3.93) Moderate preterm, n = 9 1.96 (0.93–4.13) Term, n = 38 1 [Reference] Postterm, n = 3 1.00 (0.30–3.29) 10 years, n = 175 Very preterm, n = 5 0.89 (0.36–2.18) Moderate preterm, n = 26 1.82 (1.19–2.80) Term, n = 128 1 [Reference] Postterm, n = 16 1.19 (0.71–2.01) 15 years, n = 314 Very preterm, n = 14 1.70 (0.99–2.92) Moderate preterm, n = 27 1.13 (0.76–1.69) Term, n = 241 1 [Reference] Post term, n = 32 1.07 (0.74–1.55) 20 years, n = 416 Very preterm, n = 8 0.70 (0.34–1.41) Moderate preterm, n = 31 0.98 90.68–1.42) Term, n = 323 1 [Reference] Postterm, n = 54 1.23 (0.92–1.64) 25 years, n = 456 Very preterm, n = 17 1.57 (0.96–2.56) Moderate preterm, n = 29 1.00 (0.69–1.47) Term, n = 352 1 [Reference] Postterm, n = 58 1.14 (0.86–1.51) 30 years, n = 375 Very preterm, n = 14 1.67 (0.97–2.84) Moderate preterm, n = 20 0.90 (0.57–1.41) Term, n = 292 1 [Reference] Postterm, n = 49 1.19 (0.88-1.61) 35 years, n = 204 Very preterm, n = 8 1.79 (0.88–3.65) Moderate preterm, n = 14 1.32 (0.76–2.29) Term, n = 158 1 [Reference] Postterm, n = 24 1.16 (0.75-–.79)
We also explored the findings using risk differences. We found that during the 6 to 10 years following the first pregnancy, only 12 excess T2DM cases per 10,000 women who experienced a moderate preterm birth occurred compared with women who delivered at term. By 26 to 30 years after the first pregnancy, 298 excess T2DM cases per 10,000 women who delivered a very preterm birth occurred compared with those who delivered at term.
Although term low birth weight was not associated with T2DM in the overall population (fully adjusted HR, 1.26; 95% CI, 0.88–1.81), an increased risk for women who delivered a term low birth weight infant was seen among those without a history of GDM or HDOP (fully adjusted HR, 1.62; 95% CI, 1.01–2.59). Women who gave birth to a first infant that weighed 10 pounds or more had a 1.61 increased risk of T2DM (95% CI, 1.24–2.08) (
| Term Birth Weight | N (%) | Age-adjusted Hazard Ratio (95% CI) | Adjusted Hazard Ratio (95% CI) |
|---|---|---|---|
| Term low birth weight | 554 (1.3) | 1.40 (0.98–2.01) | 1.26 (0.88–1.81) |
| Term normal birth weight | 41,294 (97.2) | 1 [Reference] | 1 [Reference] |
| Term macrosomia | 654 (1.5) | 2.96 (2.29–3.82) | 1.61 (1.24–2.08) |
Abbreviation: CI, confidence interval.
Adjusted for age in 1989.
Adjusted for maternal age at first birth, age in 1989, race/ethnicity, pre-pregnancy body mass index, family history of diabetes, menstrual irregularity, smoking during pregnancy, history of gestational diabetes mellitus, history of hypertensive disorders of pregnancy.
In our exploratory analysis evaluating time trends in risk of T2DM by 5-year intervals since first birth, we found women who had a term, low birth weight infant had an inconsistently elevated risk of developing T2DM within the first 2 decades after the first pregnancy (
Association between birth weight and type 2 diabetes among term births by 5-year intervals following first pregnancy adjusted for age at first birth, age at baseline Nurses’ Health Study II, race/ethnicity, pre-pregnancy body mass index, family history of diabetes, menstrual irregularity, smoking during pregnancy, gestational diabetes, and hypertensive disorders of pregnancy.. Abbreviations: CI, confidence interval; NA, not applicable.
Total Number of Diabetes Cases in 5-Year Intervals Adjusted Hazard Ratio (95% Confidence Interval) 5 years, n = 38
NA
Term low birth weight, n = 1
2.75 (0.37–20.51)
Term normal birth weight, n = 33
1 [Reference]
Macrosomia, n = 4
2.82 (0.97–8.18)
10 years, n = 128
NA
Term low birth weight, n = 2
1.19 (0.29–4.86)
Term normal birth weight, n = 115
1 [Reference]
Macrosomia, n = 11
1.99 (1.06–3.75)
15 years, n = 241
NA
Term low birth weight, n = 7
2.36 (1.11–5.03)
Term normal birth weight, n = 220
1 [Reference]
Macrosomia, n = 14
1.79 (1.03–3.10)
20 years, n = 323
NA
Term low birth weight, n = 7
1.64 (0.78–3.49)
Term normal birth weight, n = 301
1 [Reference]
Macrosomia, n = 15
1.79 (1.06–3.03)
25 years, n = 352
NA
Term low birth weight, n = 4
0.72 (0.27–1.94)
Term normal birth weight, n = 337
1 [Reference]
Macrosomia, n = 11
1.69 (0.93–3.09)
30 years, n = 292
NA
Term low birth weight, n = 7
1.28 (0.60–2.71)
Term normal birth weight, n = 282
1 [Reference]
Macrosomia, n = 3
0.71 (0.23–2.22)
35 years, n = 158
NA
Term low birth weight, n = 2
0.67 (0.17–2.71)
Term normal birth weight, n = 153
1 [Reference]
Macrosomia, n = 3 1.25 (0.40–3.95)
When evaluating absolute risk of T2DM for women who delivered an infant that weighed 10 pounds or more, we found an excess of 115 T2DM cases per 10,000 women in this group compared with women who delivered a normal weight infant in the 21 to 25 years following the first pregnancy. After 30 years, the elevated risk associated with having delivered a large infant had disappeared.
Because the prevalence of screening for GDM and HDOP during pregnancy has changed over the period of the births in this cohort (1964–2001), we repeated the analysis among first births occurring after the baseline 1989 questionnaire, because after that time period, screening was more widely practiced as standard care and gestational age-dating of pregnancies had probably improved with the advent of ultrasound. The hazard ratios estimated by the fully adjusted models (including GDM and HDOP diagnoses) were stronger for birth weight and T2DM, which mitigated the concern that macrosomia in the earlier pregnancies might merely be a marker for undiagnosed GDM. However, the association of very preterm delivery with T2DM was no longer detectable when limiting the analysis to pregnancies occurring after 1989.
In this study, the approximately 9% of women whose first infant was delivered preterm had excess risk of developing T2DM, even after accounting for potential medical and lifestyle confounders. The 2% of women who experienced a very preterm birth had a 34% increased risk of developing T2DM over the 35-year follow-up period. In an exploratory analysis, we found that the elevation in risk first became evident at 11 to 15 years after the first pregnancy. Postterm birth was associated with a slight, significant increase in risk of T2DM over the entire 35-year period. A history of having borne a first infant who was term low birth weight or macrosomic conferred an almost 2 to 3-fold increased risk of T2DM, which gradually waned over time. These findings held even after adjusting for GDM and HDOP, known predictors of T2DM (
In a previous study by Lykke et al based on vital statistics registry data from Denmark (
The increased risk of T2DM among women who experience a preterm birth may be due to chronic low-level inflammation (
Strengths of this study include use of a large cohort of nurses with detailed information on both pregnancy history and diabetes and information on pre-pregnancy and reproductive risk factors for diabetes. We were also able to control for GDM and HDOP as strong predictors of T2DM. In addition, this study had an average follow-up time after first birth of 22 years, which allowed for sufficient time for a substantial proportion of participants to develop the disease (approximately 4% of the population). Furthermore, we were able to explore these research questions by using different cut points in total study time. This technique allowed us to explore periods in which certain pregnancy complications may have the most predictive value for future development of T2DM. Future studies are needed to further explore and confirm these associations based on time since pregnancy.
Our study has several limitations. First, data on gestational age and birth weight were unvalidated self-reports. However, validation studies demonstrated good self-report of related pregnancy factors (
Women who experience a preterm birth or have an infant with nonnormal birth weight are not followed up for lifestyle intervention or disease prevention after re-entry into the standard health care system for nonpregnant women. Both the American Diabetes Association and American College of Obstetrics and Gynecology recommend screening for T2DM for women with a history of GDM (
This work was conducted with support from Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award no. UL1 RR 025758 and financial contributions from Harvard University and its affiliated academic health care centers). The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, or the National Institutes of Health.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions.